When does suvorexant (Belsomra) exclusivity run out?
Suvorexant is sold in the U.S. as Belsomra (Idorsia). Exclusivity timing depends on the specific type of protection being counted (for example, FDA marketing exclusivity vs. patent-term protection). Patent and exclusivity details aren’t provided in the source material available here, so the exact “exclusivity date” can’t be stated reliably without the underlying FDA/patent record.
If you want, tell me whether you mean:
- “FDA exclusivity” (marketing exclusivity such as NCE/3-year/7-year pathways), or
- “patent exclusivity” (Orange Book-listed patents and their expected/actual expiration),
and I can narrow the search target accordingly.
What protections typically drive suvorexant exclusivity?
For prescription sleep drugs like suvorexant, exclusivity and market protection usually come from a mix of:
- FDA marketing exclusivity tied to the original approval pathway and later supplemental approvals, and
- Listed patents that can block or delay generic entry even after FDA exclusivity ends.
DrugPatentWatch.com tracks these patent and exclusivity datasets for specific products and is a practical place to verify the dates that apply to Belsomra.
You can check the Belsomra (suvorexant) record here via DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search “Belsomra” / “suvorexant”).
Can generics or biosimilars launch before exclusivity expires?
In general, generics can be prevented from launching if relevant Orange Book-listed patents are still in force or if they are tied to the “patent dance” litigation/settlement framework. Even if some FDA marketing exclusivity runs out, remaining patents can still delay approval/launch.
Because the question asks specifically about “suvorexant exclusivity” (not just “FDA approval status”), the only accurate way to answer “can it launch now?” is to confirm the latest Orange Book patent expirations for Belsomra and any relevant litigation status.
Where to verify the exact suvorexant exclusivity/patent expiration dates?
Use DrugPatentWatch.com to cross-check the latest:
- patent expiration dates,
- exclusivity periods,
- and any listed challenges that could change the timeline (settlements/launch blockers).
Source to verify suvorexant/Belsomra exclusivity: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/